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Abstract
Introduction: Osteoarthritis (OA) of the knee is a common disorder affecting adults and continues to be a
growing concern as the current population ages. Intra-articular (IA) injections of hyaluronic acid (HA) are
currently used as a viscosupplementation and have shown to provide symptomatic relief. Recently the
formulation of differing molecular weight HAs have been produced to provide a further decrease in pain and
stiffness, and increase physical function. The formulations include high molecular weight HA (HMW-HA)
and low molecular weight HA (LMW-HA). The Western Ontario and McMaster Universities Osteoarthritis
Index (WOMAC) has been used as a validated tool to assess the improvements in knee OA.
Hypothesis: If pain, disability, and stiffness are affected by specific molecular weight HA, then intra-articular
injections of HMW-HA will benefit patients suffering from OA of the knee.
Study Design: A systematic review of current randomized controlled trials.
Methods: An exhaustive electronic literature search was performed for relevant published, randomized
controlled trials in MEDLINE, CINAHL, Evidence-Based Medicine Reviews Multifile, and PubMed from
January 2002 to March 2009. Inclusion criteria included randomized controlled trials comparing the effects of
intra-articular injection of high molecular weight hyaluronic acid with that of intra-articular injection of a low
molecular weight to treat osteoarthritis of the knee were included in this systematic review. Outcome
measures of pain, physical function, and stiffness based on the WOMAC had to be available. Exclusion criteria
included trials having no randomization and no pain, disability, or stiffness (WOMAC) classification.
Results: Pooled data reveal an allocation of 1321 patients to a HMW-HA, LMW-HA, or placebo group. The
average age of patients ranged from 41 to 82 years (mean 65.3 years). Of the 4 studies reviewed only one
revealed a significant difference. All others reported no significant decrease in pain and stiffness, and
improvement in physical function. Most studies demonstrated an improvement in all three variables from
baseline, independent of the molecular weight HA used.
Conclusion: Based on this systematic review of four RCTs the use of HMW-HA does not provide an absolute
clinical benefit to adult patients suffering from knee OA.
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Abstract   
 
Introduction:  Osteoarthritis (OA) of the knee is a common disorder affecting adults and continues to 
be a growing concern as the current population ages.  Intra-articular (IA) injections of hyaluronic acid 
(HA) are currently used as a viscosupplementation and have shown to provide symptomatic relief.  
Recently the formulation of differing molecular weight HAs have been produced to provide a further 
decrease in pain and stiffness, and increase physical function.  The formulations include high 
molecular weight HA (HMW-HA) and low molecular weight HA (LMW-HA).  The Western Ontario 
and McMaster Universities Osteoarthritis Index (WOMAC) has been used as a validated tool to assess 
the improvements in knee OA.  Hypothesis: If pain, disability, and stiffness are affected by specific 
molecular weight HA, then intra-articular injections of HMW-HA will benefit patients suffering from 
OA of the knee.  Study Design:  A systematic review of current randomized controlled trials.  
Methods:  An exhaustive electronic literature search was performed for relevant published, 
randomized controlled trials in MEDLINE, CINAHL, Evidence-Based Medicine Reviews Multifile, 
and PubMed from January 2002 to March 2009.  Inclusion criteria included randomized controlled 
trials comparing the effects of intra-articular injection of high molecular weight hyaluronic acid with 
that of intra-articular injection of a low molecular weight to treat osteoarthritis of the knee were 
included in this systematic review.  Outcome measures of pain, physical function, and stiffness based 
on the WOMAC had to be available.  Exclusion criteria included trials having no randomization and 
no pain, disability, or stiffness (WOMAC) classification.  Results: Pooled data reveal an allocation of 
1321 patients to a HMW-HA, LMW-HA, or placebo group.  The average age of patients ranged from 
41 to 82 years (mean 65.3 years).  Of the 4 studies reviewed only one revealed a significant difference.  
All others reported no significant decrease in pain and stiffness, and improvement in physical function.  
Most studies demonstrated an improvement in all three variables from baseline, independent of the 
molecular weight HA used.  Conclusion:  Based on this systematic review of four RCTs the use of 
HMW-HA does not provide an absolute clinical benefit to adult patients suffering from knee OA.  
 
Keywords:  Hyaluronic acid, viscosupplementation, osteoarthritis, knee 
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The Benefits of Intra-Articular High Molecular Weight Hyaluronic Acid Injections 
Compared to Low Molecular Weight Intra-Articular Hyaluronic Acid in the 
Reduction of Pain, Disability, and Stiffness in Adult Patients with Osteoarthritis of 
the Knee 
 
INTRODUCTION: 
 
Osteoarthritis (OA) of the knee is a common disorder and continues to be a growing concern in 
an aging population.  Recent estimates reveal that 46.4 million American adults (21%) are diagnosed 
with OA.  These numbers represent approximately 11.7 million ambulatory care visits a year.1   It is 
estimated that by 2020 OA will affect 59.4 million adults in the United States 1.  Due to this expected 
increase and its public health impact, management is paramount.   
The goals for management of OA of the knee are to decrease pain, improve function, and 
increase joint mobility.  Management options include analgesics (opioids, acetaminophen, and non-
steroidal anti-inflammatory drugs), intra-articular (IA) corticosteroid injections, joint arthroplasty, and 
physiotherapy, to include quadriceps strengthening and dynamic muscle balance.   
One other therapeutic treatment option is IA hyaluronic acid (HA) injections.  Hyaluronic acid, 
in the form of hyaluronan and hylan, is a major component of the synovial fluid matrix, and aids in 
joint homeostasis.  Hyaluronic acid is a polysaccharide and has been shown to influence tissue 
hydration, interact with extracellular macromolecules, and act upon cell receptors, specifically CD44.  
The therapeutic value of HA has been proposed to have a protective effect on chondrocytes and to 
improve the structural matrix within synovial fluid.  These benefits may be due to an anti-
inflammatory effect such as a decrease of phagocytosis, prostaglandin synthesis, chemotaxis, and 
removal of free radicals.2  
In patients with knee OA, hyaluronic acid is cleared from the synovial fluid at higher rates, thus 
producing a decreased concentration and molecular weight.3   Intra-articular injections of HA, referred 
to as viscosupplementation, have been shown to provide benefits after a single treatment.3   Proposed 
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mechanisms include in-situ stimulation of synovial synthesis of HAs, decreased cartilage matrix 
degradation, and suppression of inflammatory responses.4  
The formulation of differing molecular weight HAs, have been produced to compensate for the 
decreased molecular weights due to OA and to provide a joint viscosity closer to that of biological 
synovial fluid.  Currently, there are five HA formulations approved in the United States for 
viscosupplementation of knee OA: Synvisc®, Euflexxa™, Orthovisc®, Supartz™, and Hyalgan® 
(Table 1). 
The most widely used tool to assess knee OA, is the Western Ontario and McMaster 
Universities Osteoarthritis Index (WOMAC).  Moreover, the WOMAC index uses 24 parameters to 
monitor the course of the disease and/or to determine the effectiveness of anti-rheumatic medications 
(Table 3).  Scoring is based on patient response to three overall categories, which include pain, 
physical function, and stiffness.  Total maximum score is 98 with 20 from pain, 68 from physical 
function, and eight from stiffness.  The WOMAC index has been validated and deemed a reliable tool 
for assessing knee OA.5    
PURPOSE: 
The aim of this systematic review is to elucidate the therapeutic and functional benefits of 
intra-articular, high molecular weight hyaluronic acid injections for osteoarthritis of the knee in adults, 
compared to low molecular weight hyaluronic acid. 
HYPOTHESIS: 
If pain, stiffness, and the level of physical function are affected by specific molecular weight 
HA, then intra-articular injections of high molecular weight hyaluronic acid (HMW-HA) will benefit 
adult patients suffering from OA of the knee. 
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SIGNIFICANCE: 
The findings of this review will aid clinicians and healthcare providers in determining proper 
care for adult men and women suffering from OA of the knee.  Moreover, this review will determine if 
there is a beneficial effect to using a HMW-HA in the reduction of pain, disability, and stiffness in 
patients suffering from knee OA compared to low molecular weight hyaluronic acid (LMW-HA).     
METHODS: 
An exhaustive electronic literature search was performed for relevant published, randomized controlled 
trials in MEDLINE, CINAHL, Evidence-Based Medicine Reviews Multifile, and PubMed from 
January 2002 to March 2009.  The search terms, “viscosupplementation”, “osteoarthritis”, “knee”, 
“hyaluronic acid”, and its synonyms were used to refine the search.   Further limitations to the search 
criteria included humans, English language, and full text.  Each article was reviewed and assessed a 
Jadad score as a quality rating method (Table 2).  
Inclusion Criteria  
Only randomized controlled trials comparing the effects of intra-articular injection of high 
molecular weight hyaluronic acid with that of intra-articular injection of a low molecular weight to 
treat osteoarthritis of the knee were included in this systematic review.  Outcome measures of pain, 
physical function, and stiffness based on the Western Ontario and McMaster Universities 
Osteoarthritis Index (WOMAC) had to be available.  Studies must have been published within the last 
seven years (January 2002 to March 2009).  Participants must have been over 40 years of age and have 
radiographic confirmed OA of the knee. 
Exclusion criteria  
Trials having no randomization and no pain, disability, or stiffness (WOMAC) classification 
were excluded from this systematic review.  Moreover, general review and meta-analysis articles were 
excluded from the results, but referred to for background and discussion purposes only. 
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RESULTS:  
Based on the above search criteria, four randomized controlled trials (RCTs) were identified 
and found eligible for this systematic review (Table 2).  Each eligible study used the WOMAC index 
for scoring treatment effect and included all sub-categories of pain, physical function, and stiffness.  
Trial durations range from 6 to 27 weeks and only patients with a radiological confirmed diagnosis of 
knee OA were recruited.  Pooled data reveal an allocation of 1321 patients to a HMW-HA, LMW-HA, 
or placebo group.  The average age of patients ranged from 41 to 82 years (mean 65.3 years).  Listed 
below are the specific results for each study in this systematic review.        
Raman et al 6 
The high molecular (HW) hylan G-F 20 (Synvisc®) group contained 199 patients and 193 were 
allocated to the low molecular (LM) sodium hyaluronate (Hyalgan®) with predominantly grade III 
OA, 61% and 59%, respectively.  The age range was 42 to 82 years with a mean age of 67.2 years (p = 
0.54).  The gender ratio of male:female was 1:2.1 (p = 0.61).  The WOMAC scoring index 
demonstrated a significant improvement in pain scores for the HMW compared to the LMW group at 
3, 6, and 12 months (p<0.05).  Physical function WOMAC scores were significantly better in the 
HMW group compared to the LMW at 6 and 12 months (p<0.05).  There was no intergroup statistical 
difference for WOMAC stiffness, but both groups showed improvement from baseline at 3, 6, and 12 
months.  Knee pain assessed by visual analogue scale (VAS) revealed a statistical difference (p<0.05) 
between groups at 6 weeks, 6 months, and 12 months.  Adverse events were noted in 69 patients (39 
HMW and 30 LMW).  All adverse events, except one, were minor.  The major adverse event was a 
patient with pseudosepsis, which was treated per trial protocol, and subsequently excluded from the 
results.   
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Jüni et al 3 
The study evaluated IA injections of hylan (HMW), avian HA (medium molecular weight), and 
bacterial HA (LMW).  There were 660 patients randomly assigned to each group: HMW = 222 
patients, MMW = 219, and LMW = 219.  The majority of patients (57% - 60%) had confirmed 
moderate knee OA.  The mean age was 63.4 years.  Results indicated no statistical difference between 
groups for WOMAC pain score at 3 and 6 months.  Similar trends were seen for WOMAC physical 
function and stiffness scores.  There were no statistical differences between groups for VAS.   
Kotevoglu et al 7  
There were 59 patients randomly assigned to HMW (21), LMW (20), and placebo (18).  The 
mean age was 59.5 years.   The gender ratio of male:female was 1:8.5.  The HMW and LMW groups 
each exhibited a significant (p<0.05) decrease in WOMAC pain, physical function, and stiffness scores 
from baseline to 27 weeks.   No statistical difference was demonstrated between groups for WOMAC 
pain, physical function, and stiffness at all time points.  
Karlsson et al 8 
There were 210 patients randomly assigned to HMW (77), LMW (76), and placebo (57).  The 
mean age was 71.3 years.  The majority of the patients were women (68%).  The majority of the 
patients had grade I OA (59%).  There were no statistical difference between groups at all time points 
(12 and 26 weeks) for WOMAC pain, physical function, and stiffness.  Similarly, no statistical 
differences between groups were seen for VAS at all follow-up time points. 
DISCUSSION: 
Viscosupplementation with intra-articular HA injections are a treatment option for knee OA.  
Previous studies have shown a benefit using intra-articular HA when compared to placebo.2,9   Recent 
interest has been shown in the use of HMW-HAs and their added benefits compared to lower 
molecular weight HAs.  Benefits in knee OA have been quantified by using the WOMAC index, which 
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evaluates decreases in pain and stiffness, and increases in physical function (Table 3).  The WOMAC 
index is a standardized and validated scoring system used in the determination of clinical 
improvement.5     
Findings of this systematic review suggest no definitive benefits, based on the WOMAC index, 
in symptoms related to knee OA with the use of HMW-HA when compared to LMW-HA.  Three of 
the four studies found no intergroup statistical difference for pain, physical function, and stiffness 
based on the WOMAC index.3,7-8  One reviewed study, Raman et al6, demonstrated an intergroup 
difference in WOMAC pain and physical function between Synvisc® (HMW-HA) and Hyalgan® 
(LMW-HA).   
WOMAC Pain Index 
 Three of the four reviewed studies found no intergroup differences for pain based on the 
WOMAC index.  Raman et al6 demonstrated an intergroup difference when administering Synvisc® 
(6.0 mDa) (HMW) and Hyalgan® (0.5 – 0.7 mDa) (LMW).  One possible explanation for this 
intergroup difference is the use of two HA formulations at the extreme ends of the molecular weight 
spectrum.  The three other studies administered Synvisc® (6.0 mDa), but compared it to other 
viscosupplements of varying molecular weights (Table 1).  Moreover, Jüni et al3 and Kotevoglu et al7 
compared Synvisc® to Orthovisc® (1.0 – 2.9 mDa), which has a higher molecular weight than 
Hyalgan® used by Raman et al6.  The use of different formulations could be one possible explanation 
for the lack of intergroup differences.3,7-8   
 Current data show a reduction in pain with the use of viscosupplementation, independent of the 
molecular weight HA used.3,6-8  Similar results have been reported when comparing HA and a saline 
placebo IA injection.2,10  One possible explanation is the partial removal of catabolites involved in 
inflammation.  Only one of the reviewed studies specifies methodology on the injection technique 
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used.7   Moreover, an injection technique using aspiration of synovial fluid prior to HA injection may 
elicit benefits independent of the viscosupplement administered.  
WOMAC Physical Function Index 
 As previously mentioned, improving trends have been reported for LMW and HMW intra-
articular injections. 3,6-8  More specifically, these data represent an improvement in physical function 
from baseline.  These reported improvements, include ascending and descending stairs, rising from 
sitting, standing, and squatting.6,8  Most studies revealed an increase in physical function during early 
follow-up, 6 to 12 weeks, though these were not statistically significant.7,8  These results are 
independent of the molecular weight viscosupplement administered. 
 Raman et al6 did exhibit an intergroup difference for physical function when comparing 
Synvisc® and Hyalgan®.  As mentioned above, this could be attributed to the extreme difference in 
molecular weight between the two viscosupplements, although the severity of knee OA is not clearly 
stated and could be a possible limitation in extrapolating these results to clinical practice. 
WOMAC Stiffness Index 
 All reviewed studies demonstrated an intragroup improvement in stiffness from baseline.  
These results are consistent with published data from the administration of HA compared to placebo, 
independent of the molecular weight HA used.2,9   Reported improvements include decreased morning 
and evening stiffness.   
 Only one study to date has shown a significant improvement between the use of HMW HA 
compared to LMW HA.6   Other studies have been unable to reproduce these results.  The most likely 
explanation is the use of varying molecular weight HAs.  Raman et al6 administered Synvisc® and 
Hyalgan®, while other studies used Synvisc® and a HA in the mid-range of molecular weight, mainly 
Orthovisc® (1.0 – 2.9 mDa).  Moreover, the study was powered only by the primary outcome, which 
could lead to bias in the statistical analysis.6  
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Strengths of Study 
The strength of this systematic review lies in the inclusion of studies incorporating the 
WOMAC index for the assessment of a therapeutic effect in knee OA.  By assessing one primary 
outcome this provides homogeneity and makes the study reproducible.  All studies were RCTs and 
blinded, thus again adding integrity to the results.  Furthermore, each reviewed article was assessed a 
Jadad score, and these scores ranged from two to five out of a maximum of five.     
Limitations of Study 
 The current systematic review has several limitations.  First, unpublished studies were not 
searched.  Studies with negative results or limited methodology tend to be unpublished; exclusion of 
these studies may introduce the likelihood that a treatment effect is skewed in the positive direction 
due to publication bias.  Second, the four included studies differed in the viscosupplement 
administered.  Most used Synvisc® as a HMW, but differed in the LMW comparison agent.  Third, 
there was no concise standardization of knee OA severity.  Current data suggest a benefit to using 
HMW HA in patients with moderate to severe knee OA.9   The four reviewed studies stated mild to 
moderate knee OA and used two different classification systems, the Kellgren-Lawerence and Ahlbäck 
systems, to define these.  This produces heterogeneity in the results and makes it difficult to determine 
a therapeutic effect.  Lastly, by only focusing on one primary outcome, the WOMAC index, this 
current review may be overlooking other evaluation tools to reveal improvements in knee OA.  Other 
common assessment tools include the VAS, Oxford knee scores, and the EuroQol-5D index.  The 
WOMAC was used as a primary outcome measure based on its validity and incorporation of pain, 
physical function, and stiffness, and their subgroups (Table 3).  
Recommendations for Future Studies    
 More well-designed RCTs with high methodological quality are needed to fully elucidate the 
benefits of HMW HA in the treatment of knee OA.  Furthermore, double-blinded, RCTs comparing 
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Synvisc® to all varying molecular weight HAs and placebo would benefit the clinician in determining 
the best treatment for knee OA in adult patients.  The current study has noted more female patients 
than male patients enrolled in the four reviewed studies.  Future studies could analyze data to elicit a 
possible gender effect associated with the administration of HMW-HA and/or LMW-HA.  
 Synvisc-One™ is a new viscosupplement touted to give benefits up to six months.  Future 
studies comparing this, to track proven HA agents would shed more light on the treatment options 
available to clinicians.  Furthermore, Synvisc-One could show clinical benefits by reducing the number 
of injections patients need, decreasing adverse events, and reducing of out-of-pocket cost.     
CONCLUSION 
 Based on this systematic review of four RCTs, the use of HMW-HA does not provide an 
absolute clinical benefit to patients suffering from knee OA.  Furthermore, there is no definitive 
therapeutic effect of HMW-HA compared to other proven modalities, such as NSAIDs, IA 
corticosteroid injections, physiotherapy, and joint arthroplasty.  The current recommendations for knee 
OA are to begin with noninvasive therapies (NSAIDs and physiotherapy) and progress to more 
invasive techniques (IA corticosteroid and HA injections).  Lastly, total joint arthroplasty is a 
definitive treatment for knee OA, but is reserved for patients suffering from severe OA.   
 
 
 
 
 
 
 
 
 
17 
 
TABLE 1:  Current FDA Approved Hyaluronic Acid Products in the United States 
Compound Name Molecular Weight 
(Daltons) 
Dosage per Injection Number of 
Injections 
Synvisc® (Hylan G-F 20) 6.0 x 106 16mg/2mL 3 
Euflexxa™ (1% sodium 
hyaluronate) 
2.4 – 3.6 x 106 10mg/2mL 3 
Orthovisc® (Hyaluronan) 1.0 – 2.9 x 106 30mg/2mL 3 or 4 
Supartz™ (Sodium 
hyaluronate) 
0.6 – 1.2 x106 25mg/2.5mL 3 or 5 
Hyalgan® (Sodium 
hyaluronate) 
0.5 – 0.7 x 106 20mg/2mL 3 or 5 
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TABLE 2:  Study Characteristics of Four Reviewed Articles 
Author and 
Year 
Study Type Patients HA Administered Outcomes Jadad 
Score 
Raman et al 
2008 
Prospective 
RCT, 
Investigator 
blinded 
n = 380 Synvisc x 3 (HMW) 
Hyalgan x 5 (LMW) 
WOMAC, 
VAS, & 
Oxford 
Knee Score 
3 
Jüni et al 2007 RCT, Patient 
blinded 
n = 330 Synvisc x 3 (HWW) 
Orthovisc x 3 (MMW) 
Ostenil x 3 (LMW) 
WOMAC & 
VAS 
2 
Kotevoglu et 
al 2004 
RCT & Double 
blinded 
n = 59 Synvisc x 3 (HMW) 
Orthovisc x 3 (LMW) 
WOMAC 3 
Karlsson et al 
2002 
RCT, Double 
blinded, 
Placebo 
controlled 
n = 242 Synvisc x 3 (HMW) 
Artzal x 3 (LMW) 
WOMAC, 
VAS, & 
Lequesne 
5 
HMW = high molecular weight; MMW = medium molecular weight; LMW = low molecular weight; WOMAC = Western 
Ontario and McMaster Universities Osteoarthritis Index; VAS = visual analogue scale 
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Table 3: The WOMAC Index 
The WOMAC Index 
Categories Pain Physical Function Stiffness 
Sub-Categories Walking 
Stair climbing 
Nocturnal 
Rest 
Weight bearing 
Descending stairs 
Ascending stairs 
Sitting 
Rising from sitting 
Standing 
Lying 
Riding from bed 
Bending to floor 
Walking on flat 
Getting in and out of car 
Going shopping 
Putting on socks 
Taking socks off 
Morning stiffness 
Stiffness occurring later 
in the day 
WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index 
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